Crescent Biopharma, Inc. (CBIO): Capital Expenditures
$919.0K
Year ended 2025-12-31
$939.0K
Trailing 12 months to 2026-06-30
+121.8%
3-year compound annual growth
+68.1%
5-year compound annual growth
+13.1%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $919.0K | n/m | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $10.0K | -53.4% | 2025-02-13, From 2024-01-01 |
| 2023-12-31 | $21.4K | -74.6% | 2025-02-13, From 2023-01-01 |
| 2022-12-31 | $84.2K | +463.4% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $14.9K | -78.2% | 2024-03-27, From 2021-01-01 |
| 2020-12-31 | $68.5K | -52.7% | 2023-03-29, From 2020-01-01 |
| 2019-12-31 | $144.9K | +15.4% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $125.6K | -57.3% | 2021-03-02, From 2018-01-01 |
| 2017-12-31 | $294.1K | -58.2% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $704.2K | +162.2% | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | $268.6K | +26.3% | 2018-03-06, From 2015-01-01 |
| 2014-12-31 | $212.6K | +159.0% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $82.1K | -74.0% | 2016-02-29, From 2013-01-01 |
| 2012-12-31 | $316.2K | n/a | 2015-03-16, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $919.0K | n/m |
| Jaguar Health, Inc. (JAGX) | 2024-12-31 | $16.0K | n/a |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $1.04M | +190.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $18.0K | -86.3% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $67.0K | -91.2% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $2.00M | -76.8% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $1.0K | -91.7% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $43.0K | -74.1% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $235.0K | +167.0% |
Compare CBIO, JAGX, JANX, ZBIO side by side · Screen every company in Pharmaceutical Preparations ↗